Executive Functions in Elite Athletes
NCT05488600, Completed, Istanbul Medipol University Hospital
Trial 9
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
| Field | Value | Source |
|---|---|---|
| Title | Executive Functions in Elite Athletes | ClinicalTrials.gov |
| NCT number | NCT05488600 | ClinicalTrials.gov |
| Status | Completed | ClinicalTrials.gov |
| Enrollment | 90 participants, actual | ClinicalTrials.gov |
| Lead sponsor | Istanbul Medipol University Hospital | ClinicalTrials.gov |
| Conditions | Cognitive Change | ClinicalTrials.gov |
| Interventions | Executive Function Assessment | ClinicalTrials.gov |
| First posted | 2022-08-04 | ClinicalTrials.gov |
| Last updated | 2022-10-04 | ClinicalTrials.gov |
Registered outcomes 4
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description | Source |
|---|---|---|---|---|
| Primary | London Tower Test | day 1 | The Tower of London test is an executive function test that is particularly sensitive to planning and problem-solving skills. The Tower of London test consists of 2 tower boards and red, blue and green beads. The participant is asked to make the same shape on the tower board of the tester opposite him on his own tower board in the fewest moves. A low total score and a high correct total score indicate good planning and problem-solving abilities. The high score of total rule mistake indicates the negativities in the ability to acquire and control planning and problem-solving behavior under certain rules. The excess of the total time out indicates the difficulty in planning and problem-solving skills at a certain time. The shortness of the onset time indicates effective planning before the problem-solving response begins. The application time and the shortness of the total time indicate the speed of problem-solving. | ClinicalTrials.gov |
| Secondary | Digit Span Test | day 1 | The test consists of two parts forward and backward span. The participant is asked to repeat the numbers read in one second intervals in the forward span in the same order. It assesses attention, concentration and short-term memory. In the backward span, the numbers read at one-second intervals are requested to be repeated in reverse order from the end to the beginning. Working memory, which is a component of executive functions, is evaluated. The highest score that can be obtained for the forward span is 8 points, and 7 for the backward span, for a total of 15 points. | ClinicalTrials.gov |
| Secondary | Stroop Test | day 1 | The Stroop test evaluates inhibitory control, which is a component of executive functions. On the card we used as test material, the words blue, green, red, yellow are written and painted in a different color than the word. The person is first asked to read the colored words printed unrelated to the color. In the second step, the person is asked to say the color of the colored words written unrelated to the color on which they are printed. The time from the "start" command to the end, the number of errors and corrections are recorded. The time difference between the two stages constitutes the interference score. Error and correction numbers are calculated. The long duration of interference, errors and corrections indicate that the person's attention is easily distracted and cannot suppress inappropriate stimuli. | ClinicalTrials.gov |
| Secondary | Trail Making Test | day 1 | The Trail Making test consists of two parts, A and B. In part A, the participants are asked to combine the circles with numbers randomly scattered on the paper in the correct order and follow each other (1-2-3-4-5...). In section B, there are letters and numbers randomly placed in circles. Participants are asked to combine a letter and a number in the correct sequence (1-A-2-B-3-C-4-D...) consecutively. Time is kept for both sections. The duration is expected to be short. The A part of the TMT evaluates the processing speed based on visual scanning ability, and the B part evaluates the complex attention, planning, set changing, inhibition ability, and following the sequencing. | ClinicalTrials.gov |
Outcomes 0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
| Type | Outcome | Time frame | Population | Units | Measured as | Source |
|---|
Results by group 0
Each measurement the trial posted, group by group, in the words and numbers it posted.
| Outcome | Group | Category | Value | Spread | Units | Source |
|---|
Participant flow 0
How many started, completed or left each group, period by period.
| Period | Milestone | Group | Participants | Units counted | Source |
|---|
Adverse events 0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
| Type | Event | Organ system | Group | Affected | At risk | Events | Source |
|---|
Adverse event totals 0
The totals the trial posted for each group.
| Total | Group | Affected | At risk | Source |
|---|
Papers 2
The papers the trial lists on ClinicalTrials.gov.
Grants 0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
| Project | Title | Principal investigators | Organization | Funder | Fiscal years | Source |
|---|
Trial comparisons 0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
| Comparison | Source |
|---|
Tests 5
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
| Test | Named as | Source |
|---|---|---|
| Tower Planning | Primary outcome | ConductCognition |
| Digit Span Test | Secondary outcome | ConductCognition |
| Stroop Color-Word Test | Secondary outcome | ConductCognition |
| Trail Making Test A | Secondary outcome | ConductCognition |
| Trail Making Test B | Secondary outcome | ConductCognition |
Source 5
| Field | Value | Source |
|---|---|---|
| Release | trials-2026-11-12-0.4.0 | ClinicalTrials.gov |
| Release manifest SHA-256 | 0f4a8d8c48aee2a7573ae0fa94ecbeab70c1adbe449bbc95c424bc7d3e97b9d4 | ClinicalTrials.gov |
| Registry capture | 2026-11-12 | ClinicalTrials.gov |
| Results copy, AACT | 2026-03-23 | ClinicalTrials.gov |
| NIH clinical studies file | 2026-11-13 | ClinicalTrials.gov |
Release trials-2026-11-12-0.4.0
ClinicalTrials.gov's posted results, through CTTI's AACT: ClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299 ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
ClinicalTrials.gov: none stated ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
NIH RePORTER's clinical studies and project files: Public domain (NIH RePORTER)